Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 8-K (Current Report)
Date of Report: May 31, 2024
Event: Entry into a Material Definitive Agreement involving the inducement exercise of existing warrants and the issuance of new warrants.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $2.1 million in cash from the exercise of existing Series B and Series C warrants.
- Shares Issued: 10,698,000 shares of common stock issued upon immediate exercise of existing warrants.
- Exercise Price (Existing Warrants): Reduced from $0.60 to $0.20 per share for the inducement exercise.
- New Securities Issued:
- Series B-1 Warrants: 2,673,000 shares at $0.20 exercise price (5-year term).
- Series C-1 Warrants: 8,025,000 shares at $0.20 exercise price (5-year term).
- New Series D Warrants: 10,698,000 shares at $0.30 exercise price (66-month term), issued as consideration for the inducement.
- Transaction Costs:
- Placement Agent Fee (Ladenburg Thalmann & Co.): 8.0% of gross proceeds.
- Management Fee: 1.0% of gross proceeds.
- Reimbursement of accountable legal expenses.
- Use of Proceeds: General corporate purposes.
Material Changes and Transaction Structure
The Company entered into an Inducement Letter with 9 holders of existing warrants issued on April 18, 2024. The material change involves the immediate exercise of these warrants at a significantly reduced price ($0.20 vs. original $0.60) in exchange for the issuance of new, unregistered Series D warrants. The closing date for the issuance of the New Series D Warrants is expected to be June 3, 2024.
Guidance, Outlook, and Restrictions
- Registration Obligations: The Company agreed to file a Form S-1 Resale Registration Statement within 6 months of the Closing Date for the common stock underlying the New Series D Warrants and keep it effective until all such warrants are exercised or expired.
- Lock-up Restrictions:
- 30-day moratorium on issuing or announcing the issuance of common stock or equivalents (with exceptions for employee plans).
- 6-month moratorium on entering into variable rate financing (with exceptions).
- Regulatory Status: The New Series D Warrants are issued pursuant to Section 4(a)(2) and Regulation D exemptions and are not registered under the Securities Act.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 9% total fees (8% placement + 1% management) and legal expenses.
- Confirm the dilution impact of the 10,698,000 shares issued immediately plus the 10,698,000 shares underlying the new Series D warrants.
- Monitor the filing and effectiveness of the required Form S-1 Resale Registration Statement within the 6-month window.
- Review the Company's cash runway and burn rate to assess the sufficiency of the $2.1 million gross proceeds for "general corporate purposes."
- Check for any subsequent filings regarding the satisfaction of closing conditions for the June 3, 2024 closing date.